0001193125-26-219482
SEC filingRevenue collapsed 99.5% as the prior-year period included a one-time milestone from manufacturing transfer to Pierre Fabre, while operating losses narrowed sharply on aggressive cost restructuring.
Operating income swung from a profit of $38.8M in Q1 2025 to a loss of $3.4M in Q1 2026, a decrease of 108.7%. The loss narrowed significantly from the prior-year operating profit due to reduced headcount following the 2025 reductions in force and lower research and development expenses. Net income was a loss of $4.1M compared to income of $38.0M in the prior year, with diluted EPS of ($0.29) versus $3.50.
Net cash used in operating activities improved to $3.1M from $28.1M in Q1 2025, reflecting lower compensation and clinical trial costs. The company continues to manage cash carefully, investing excess cash with a focus on liquidity and capital preservation. However, management expects to continue generating losses and anticipates that significant additional capital will be needed to fund planned operations.
In January 2026, the FDA issued a second Complete Response Letter for the tab-cel BLA, stating that the ALLELE trial is no longer considered an adequate and well-controlled study due to deficiencies in design, conduct, and analysis. While GMP compliance issues from the first CRL were resolved, this new hurdle delays U.S. approval. In April 2026, Pierre Fabre held a productive Type A meeting with the FDA, which agreed that a single-arm study with an appropriate historical control could support a future marketing application. A regulatory update is expected in Q3 2026. The path to U.S. approval remains uncertain and will require additional clinical work.
The company has no committed external funding beyond potential milestone and royalty payments from Pierre Fabre, which are subject to the HCRx Agreement and unlikely to provide meaningful near-term cash. Management continues to evaluate strategic alternatives, but the combination of a depleted cash position, a single product candidate facing regulatory delays, and a minimal operating structure leaves the company in a precarious position. Investors should monitor the outcome of the strategic review process and the regulatory path for tab-cel as the primary value drivers.